Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lingdolinurad - Atom Therapeutics

Next Previous
Drug Profile

Lingdolinurad - Atom Therapeutics

Alternative Names: ABP-671

Latest Information Update: 09 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atom Bioscience
  • Developer Atom Therapeutics
  • Class 2 ring heterocyclic compounds; Alkanes; Antigouts; Antirheumatics; Bromobenzenes; Imidazoles; Ketones; Nitriles; Phenols; Pyridines; Small molecules; Uricosurics; Urologics
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gout
  • Phase II Hyperuricaemia
  • Phase I Renal failure

Most Recent Events

  • 09 Feb 2026 Preclinical trials in Gout (Treatment-resistant) in China (PO) (Atom therapeutics pipeline, February 2025)
  • 26 Jan 2026 Atom Therapeutics plans a phase I for Gout (Combination-therapy) in the US (NCT07367971)
  • 07 Jan 2026 Atom Therapeutics plans a phase II trial for Renal failure and Hyperuricaemia in China and Australia in February 2026 (PO) (NCT07323095)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top